



INCIDENT COMMAND COVID-19 MISSION ASSIGNMENTS

Monoclonal Antibody (mAb) Weekly Report

REPORT DATE	October 18, 2021
DATA DATE	October 6 – 12, 2021
NOTES	Per agreement with monoclonal antibody partners, and to keep in alignment with Federal mAb reporting, the data collection periods are from Wednesday to Tuesday each week. In order to validate and verify data submission, correct as needed, and compile report, this report will be provided on Monday each week. Report Monday 10/25 – Treatment data Wednesday 10/13 – Tuesday 10/19 Report Monday 11/1 – Treatment data Wednesday 10/20 – Tuesday 10/26 Report Monday 11/8 – Treatment data Wednesday 10/27 – Tuesday 11/2

MONOCLONAL ANTIBODIES ALLOCATION, UTILIZATION, AND ORDERED AMOUNT

Program Week	Allocation to Utah	Ordered Amount	Utilization Reported
Wed-Tue 9/22 – 9/28	1,608	1,608	503 (incl. 40 UDOH)
Wed-Tue 9/29 – 10/5	1,740	1,740	458 (incl. 54 UDOH)
Wed-Tue 10/6 – 10/12	1,896	624	552 (incl. 102 UDOH)
Wed-Tue 10/13 – 10/19	2,134	744	Due 10/20
Wed-Tue 10/20 – 10/26	2,050	Due 10/22	Due 10/27

For the most current reporting week of 10/6 to 10/12, the following items provide detail on the 552 treatments:
 UDOH Monoclonal Strike Teams (MIST) – 102 treatments (56 mobile response, 46 fixed site) (18%)
 Hospital systems/skilled nursing self-administration aggregate – 450 treatments (82%)

Administrations in all partners by geography:

Wasatch Front (SL, UT, WE, DA) locations: 370 treatments (67%)

Other counties 182 treatments (33%)

Administrations by system affiliation:

Big 4 administrations (UU, Intermountain, Steward, MountainStar: 347 treatments (63%)

All others 205 treatments (37%)

UDOH and hospital partners are well supplied with inventory at this time, reporting almost 2,400 treatments in stock, and several report running out of space to hold the treatments, increases in order quantity will increase as needed to maintain adequate stock over subsequent program weeks.

Details here - <https://www.phe.gov/emergency/events/COVID19/therapeutics/distribution/Pages/data-tables.aspx> and current allocations attached as appendices to this document.

NOTES AND NEXT STEPS

Completed

- Hospital capacity has been maximized, reporting noted as 448 treatments last week on an estimated 420/week capacity.
- The UDOH joint mobile and fixed mission increased from 54 to 102, an increase of almost 90%, even though the week was short due to the holiday.
- Adequate staffing was secured for the MIST fixed and mobile, including the assignment of 3 UTNG and opening direct hires through UHERT to fully staff this mission.
- Website overhaul is completed to provide patient centered access and information about available treatments. <https://coronavirus.utah.gov/noveltherapeutics/>
- A banner button has been included on the homepage of coronavirus.utah.gov to provide clear and direct access to the program.
- Provided technical assistance to hospitals and other participating partners to direct patients to website and risk score calculator first, to increase the self-screening

In-Progress

1. MaB partner reporting compliance now exceeds 95% into the state Redcap survey, our data team will work with the partners to get to 100%. Accurate and timely reporting allows us to closely track treatments provided, inventory in stock, and requested order volumes for all partners.
2. UDOH is in final stages of contracting with Nomi to establish a Wasatch South fixed site in Orem.
3. UDOH has partnered with Davis Hospital and Nomi to include their infusion centers into a shared scheduling model to ensure that they can get treatments scheduled at the newly established sites.
4. UDOH has engaged Case Investigation team and all testing partners to include a reminder for patients to go to the website and determine if they are eligible for mAb treatment.
5. UHA has established a monoclonal strategic working group with key leaders from hospitals.
6. UDOH has activated monitoring of webpage, social media, outdoor media to drive access, interest and messaging.
7. UDOH, in partnership with Poison Control hotline, continue to provide assistance for scheduling, troubleshoot access gaps for patients, and provide individual patient support as needed.



HOME PAGE

HEALTH GUIDANCE LEVELS

UPDATES


INFORMATION FOR...

EN ESPAÑOL

Where can I get vaccinated?

Where can I get tested?

Monoclonal Antibody Therapy



Monoclonal Antibodies:
Would you benefit from mAb?



Monoclonal Antibodies:
High risk with symptoms?
Get tested immediately to qualify.



Monoclonal Antibodies:

- ✓ **If you test positive for COVID-19**
- ✓ **At high-risk**
- ✓ **Symptoms less than 7 days**

